Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2006; 12(35): 5692-5698
Published online Sep 21, 2006. doi: 10.3748/wjg.v12.i35.5692
Published online Sep 21, 2006. doi: 10.3748/wjg.v12.i35.5692
Table 6 Comparison of side effects in both hepatitis C groups
| Variable | Group A | Group B | P |
| Flu-like symptoms | 40 (100.0) | 40 (100.0) | |
| Discontinuation of drug | 0 (0) | 0 (0) | NS1 |
| Thyroid dysfunction | 2 | 3 | NS1 |
| Discontinuation of drug | 1 | 2 | |
| Psychological upset and drug intolerability | 1 | 1 | NS1 |
| Discontinuation of drug | 1 | 1 | |
| Hematological | |||
| Anemia (30% from baseline) | 13 (26.0) | 12 (24.0) | NS1 |
| Neutropenia (< 0.9 × 109/L) | 21 (42.0) | 19 (38.0) | NS1 |
| Thrombocytopenia (< 50 × 109/L) | None | 2 (4) | NS1 |
- Citation: Derbala M, Kaabi SA, Dweik NE, Pasic F, Butt M, Yakoob R, Al-Marri A, Amer A, Morad N, Bener A. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006; 12(35): 5692-5698
- URL: https://www.wjgnet.com/1007-9327/full/v12/i35/5692.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i35.5692